C R Sumner

Summary

Affiliation: Eli Lilly and Company
Country: USA

Publications

  1. ncbi Telepsychiatry: challenges in rural aging
    C R Sumner
    Eli Lilly and Company, Indianapolis, IN 46221, USA
    J Rural Health 17:370-3. 2001
  2. ncbi Placebo-controlled study of the effects of atomoxetine on bladder control in children with nocturnal enuresis
    Calvin R Sumner
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    J Child Adolesc Psychopharmacol 16:699-711. 2006
  3. ncbi Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial
    Douglas K Kelsey
    Lilly Research Laboratories, Indianapolis, Indiana, USA
    Pediatrics 114:e1-8. 2004
  4. ncbi Decreased use of clonidine following treatment with atomoxetine in children with ADHD
    Joseph A Johnston
    US Outcomes Research, Lilly Research Laboratories, Lilly Technology Center, DC 5024, Indianapolis, IN 46285, USA
    J Clin Psychopharmacol 26:389-95. 2006
  5. ncbi Efficacy and safety of atomoxetine in adolescents with attention-deficit/hyperactivity disorder and major depression
    Mark E Bangs
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, USA
    J Child Adolesc Psychopharmacol 17:407-20. 2007
  6. ncbi Effects of atomoxetine on attention-deficit/hyperactivity disorder in clinical pediatric treatment settings: a naturalistic study
    Rosalie J Bakken
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Curr Med Res Opin 24:449-60. 2008
  7. ncbi Improvement in health-related quality of life in children with ADHD: an analysis of placebo controlled studies of atomoxetine
    Amy R Perwien
    Outcomes Research, US Medical Division, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    J Dev Behav Pediatr 25:264-71. 2004

Collaborators

Detail Information

Publications7

  1. ncbi Telepsychiatry: challenges in rural aging
    C R Sumner
    Eli Lilly and Company, Indianapolis, IN 46221, USA
    J Rural Health 17:370-3. 2001
    ..Advances in telepsychiatry technology allow a core group of skilled mental health providers in a central location to provide timely local access to quality services for the rural elderly over a broad geographic area...
  2. ncbi Placebo-controlled study of the effects of atomoxetine on bladder control in children with nocturnal enuresis
    Calvin R Sumner
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    J Child Adolesc Psychopharmacol 16:699-711. 2006
    ..This study tested the hypothesis that atomoxetine will provide significant therapeutic benefit for nocturnal enuresis in patients with the diagnosis of nocturnal enuresis...
  3. ncbi Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial
    Douglas K Kelsey
    Lilly Research Laboratories, Indianapolis, Indiana, USA
    Pediatrics 114:e1-8. 2004
    ..Another goal was to determine how early in treatment it was possible to discern a specific effect of the drug on ADHD symptoms...
  4. ncbi Decreased use of clonidine following treatment with atomoxetine in children with ADHD
    Joseph A Johnston
    US Outcomes Research, Lilly Research Laboratories, Lilly Technology Center, DC 5024, Indianapolis, IN 46285, USA
    J Clin Psychopharmacol 26:389-95. 2006
    ..In others, atomoxetine has replaced both stimulant and clonidine in patients previously requiring this combination for the control of symptoms or for the management of stimulant-related adverse effects...
  5. ncbi Efficacy and safety of atomoxetine in adolescents with attention-deficit/hyperactivity disorder and major depression
    Mark E Bangs
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, USA
    J Child Adolesc Psychopharmacol 17:407-20. 2007
    ..ATX was an effective and safe treatment for ADHD in adolescents with ADHD and MDD. However, this trial showed no evidence for ATX of efficacy in treating MDD...
  6. ncbi Effects of atomoxetine on attention-deficit/hyperactivity disorder in clinical pediatric treatment settings: a naturalistic study
    Rosalie J Bakken
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Curr Med Res Opin 24:449-60. 2008
    ....
  7. ncbi Improvement in health-related quality of life in children with ADHD: an analysis of placebo controlled studies of atomoxetine
    Amy R Perwien
    Outcomes Research, US Medical Division, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    J Dev Behav Pediatr 25:264-71. 2004
    ..Findings demonstrate the positive impact of atomoxetine on HRQL in children with ADHD...